Attention Deficit Hyperactivity Disorder
Conditions
Keywords
ADHD, methylphenidate, omega-3
Brief summary
It is assumed that only 1/5 of children diagnosed with attention-deficit-hyperactivity disorder (ADHD) are treated. New treatment modalities are urgently needed. Omega-3 fatty acids have been used in this setting, yet results are conflicting. The parent omega-3 fatty acid alpha-linolenic acid (ALA) has only been used in one trial. 40 children diagnosed with ADHD will be randomized to consume either ALA or placebo for two months. Baseline and end assessments will include ADHD-related questionnaires and a computerized test. The investigators hypothesize that ALA supplementation will prove beneficial for children with ADHD.
Interventions
DIETARY_SUPPLEMENTomega-3 fatty acid alpha-linolenic acid (ALA)
3 grams of ALA-containing plant oil
DIETARY_SUPPLEMENTPlacebo
Sponsors
Israel Association of Pediatricians
Hadassah Medical Organization
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
6 Years to 16 Years
Healthy volunteers
No
Inclusion criteria
* ADHD diagnosis * informed consent
Exclusion criteria
* refusal of any testing * any comorbidities * any medication or supplement use
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| ADHD symptoms | 8 weeks | scores of DSM and Conners questionnaires |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Computerized test performance | 8 weeks | performance in a computerized test of attention |
Countries
Israel
Outcome results
None listed